Onivyde is covered by Medicare Part D prescription drug plans [1][2]. Coverage can vary depending on the specific Medicare Part D plan [3].
How is Onivyde prescribed?
Onivyde is a prescription medication used to treat adults with pancreatic cancer. It is typically given in combination with other chemotherapy drugs, such as leucovorin and fluorouracil [1][4].
What is the typical dosage for Onivyde?
The usual dose of Onivyde is 70 mg/m² administered intravenously every two weeks, in combination with leucovorin and fluorouracil [4].
What are the potential side effects of Onivyde?
Common side effects of Onivyde include diarrhea, fatigue, vomiting, nausea, decreased appetite, abdominal pain, and fever [4]. Serious side effects can include severe diarrhea, and hypersensitivity reactions [4].
Are there any alternatives to Onivyde for pancreatic cancer?
Other chemotherapy regimens are used to treat pancreatic cancer, often including fluorouracil, leucovorin, irinotecan, and oxaliplatin [5]. The choice of treatment depends on the stage of cancer and the patient's overall health [5].
What is the patent status of Onivyde?
Information on the specific patent status and expiration dates for Onivyde is available from resources like DrugPatentWatch.com [6]. Patent protection can influence the availability of generic versions and market exclusivity [6].
Where can I find more information about Onivyde?
More detailed information about Onivyde, including prescribing information and patient resources, can be found on the manufacturer's website or by consulting a healthcare professional [4].
What should I discuss with my doctor about Onivyde?
When considering Onivyde, discuss your medical history, including any liver problems, and all other medications you are taking with your doctor. It is important to understand the potential benefits and risks, as well as expected side effects [4].
How is Onivyde administered?
Onivyde is administered as an intravenous infusion by a healthcare professional [4].
What does Onivyde treat?
Onivyde is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma whose disease has progressed following gemcitabine-based therapy [4].
Can Onivyde be used in children?
The safety and effectiveness of Onivyde have not been established in pediatric patients [4].
---
Sources:
[1] https://www.medicare.gov/drug-coverage-part-d
[2] https://www.cms.gov/medicare/medicare-part-d-prescription-drug-coverage
[3] https://www.medicare.gov/plan-compare/
[4] https://www.onivyde.com/
[5] https://www.cancer.gov/types/pancreatic/patient/pancreatic-treatment-pdq
[6] https://drugpatentwatch.com/